Hand, foot and mouth disease: common, usually mild, rarely dangerous

Hand, foot and mouth disease is a common viral infection of early childhood that in the great majority of children is mild and resolves without any specific treatment [s2]. There is no antiviral that cures it — care is supportive — so the evidence worth knowing is not about a treatment but about the illness's natural course and the rare, serious minority of cases [s2].

What it is, and who gets it

The illness is caused by enteroviruses, a family of small viruses, and it occurs most commonly in children five years of age or younger [s2]. The typical presentation is a fever alongside painful mouth ulcers (herpangina) and a rash of spots or blisters on the hands and feet [s2]. The two viruses most often responsible are coxsackievirus A16 and enterovirus A71, and a country-level synthesis of global data published in 2026 found that a third virus, coxsackievirus A6, is now circulating more widely across multiple regions [s3]. That synthesis also noted that reported cases fell during the COVID-19 pandemic and then rebounded in many settings, in some exceeding pre-pandemic levels [s3].

The disease has historically been reported most in the Asia-Pacific region, and that is also where surveillance is concentrated, so the global picture is genuinely incomplete [s3]. The best population-scale data therefore come from China, which runs enhanced national surveillance.

What the numbers show about severity

The single largest study of the disease drew on cases reported to the Chinese Center for Disease Control and Prevention between 1 January 2008 and 31 December 2012 [s1]. The registry held 7,200,092 probable cases, an annual incidence of 1.2 per 1,000 person-years across 2010-12, of which 267,942 (3.7 percent) were laboratory confirmed and 2,457 (0.03 percent) were fatal [s1]. Both incidence and mortality were highest in the youngest children: those aged 12 to 23 months had 38.2 cases per 1,000 person-years in 2012 [s1]. The median time from onset to diagnosis was 1.5 days [s1].

Those figures set the severe cases in proportion. Across the five years, 82,486 patients developed cardiopulmonary or neurological complications — a case-severity rate of 1.1 percent — and among those with severe disease the fatality rate was 3.0 percent [s1]. Crucially, the deaths were not spread evenly across the viruses: 1,617 of 1,737 laboratory-confirmed deaths, or 93 percent, were associated with enterovirus A71 [s1]. In other words, the ordinary case is mild and self-limiting, while the small burden of death and serious harm is concentrated in the very young and in one particular virus.

Why there is no pill for it

Because the illness is caused by enteroviruses and is usually self-limiting, there is no specific licensed antiviral treatment; management is supportive — fluids and pain relief for the mouth ulcers — and the review literature frames the absence of adequate treatment as precisely the reason vaccine development has become a prevention priority [s2]. Progress on that front has been almost entirely against enterovirus A71, the virus that drives the severe cases; developing vaccines has been identified as a priority for preventing enterovirus infections for which there is no adequate treatment [s2]. No vaccine addresses the coxsackieviruses that cause most ordinary cases, which is one reason the shift toward coxsackievirus A6 that surveillance is now picking up matters [s3].

That leaves prevention resting on hygiene and containment rather than immunity. This is a viral illness, so — as with the common cold — antibiotics do nothing for it, a point we set out in why antibiotics don't work on colds.

What actually warrants concern

The honest reading of the evidence is reassuring for most families and specific about the exception. The disease is common, the typical course is mild, and the fatal or severe outcome is rare and concentrated in children under two and in enterovirus A71 infection [s1]. The features that separate an ordinary case from the rare dangerous one are the systemic ones — persistent high fever, lethargy, and signs of neurological or breathing trouble — which is the same "is this child seriously unwell?" judgement that underlies the traffic-light system for assessing a febrile child. It sits alongside other common childhood viral illnesses, such as croup, where the evidence-based approach is to treat the child's comfort and watch for the small number of red flags rather than to reach for a cure that does not exist.

How to read this

For an individual child in a high-income setting, hand, foot and mouth disease is overwhelmingly likely to be a mild, brief illness that needs comfort, not intervention [s1][s2]. The population data explain why it is nonetheless taken seriously: at national scale a fraction of a percent of cases turn severe, that fraction skews young, and it is dominated by one virus, against which the only real countermeasure is a vaccine that is not universally available [s1][s3]. This article is informational and is not medical advice; a child who is drowsy, breathing abnormally, or not drinking needs prompt medical assessment.